SEC Form 4

1

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	. 0.5							

1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer Gallagher Cam 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Person(s) to Issuer (C/O ZENTALIS PHARMACEUTICALS, INC. 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable) (Street) NEW YORK 10018 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable) X Form filed by More than One Reporting Person Form filed by More than One Reporting Person	Instruction 1(b).	continue. See	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response: 0.5		
Gallagher Cam Zentalis Pharmaceuticals, Inc. [ZNTL] (Check all applicable) (Last) (First) (Middle) C/O ZENTALIS PHARMACEUTICALS, INC. 3. Date of Earliest Transaction (Month/Day/Year) 03/07/2022 (Street) Vertical of Address of Nepolating Tensor 6. Individual or Joint/Group Filing (Check Applicable Line) NEW YORK NY 10018							_
(Last) (First) (Middle) C/O ZENTALIS PHARMACEUTICALS, INC. 3. Date of Earliest Transaction (Month/Day/Year) below) below) 1359 BROADWAY, SUITE 1710 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) X. Form filed by One Reporting Person Form filed by More than One Reporting		1 0	on*	• ·	(Check all applica		
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) X Form filed by One Reporting Person NEW YORK NY 10018	C/O ZENTALIS	PHARMACEUT	TICALS, INC.			ive title	
	(Street) NEW YORK	NY	10018	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X Form file Form file	Form filed by One Reporting Person	
(City) (State) (Zip)	(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			3, 4 and 5) Securities Beneficially Owned Following		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(1150.4)
Common Stock	03/07/2022		S ⁽¹⁾		9,477	D	\$44.9044(2)	376,336	D	
Common Stock	03/07/2022		S ⁽¹⁾		523	D	\$ 45.5607 ⁽³⁾	375,813	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

								-				-			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021.

2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$44.34 to \$45.33. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$45.55 to \$45.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

By: /s/ Melissa B. Epperly, 03/08/2022 Attorney-in-Fact for Cam S.

Gallagher

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.